History of combined protection: 25 years of using the fixed-dose combination of amlodipine and bisoprolol in clinical practice

Sergey R. Gilyarevsky , Maria V. Golshmid , Nana G. Bendeliani , Irina M. Kuzmina

For citation:

Abstract

The paper discusses the role of Concor AM, the fixed-dose combination of amlodipine and bisoprolol, which has been used in clinical practice for treatment of patients with cardiovascular diseases for 25 years. The data are provided on the benefits of using Concor AM in treatment of patients with arterial hypertension and coronary artery disease. Evidence is discussed that illustrated the advantages of using such fixed-dose combination compared to the combination use of amlodipine and bisoprolol in the form of the so-called free combination. The evidence also includes the results of the recently completed randomized clinical trial that involved comparative analysis of the use of Concor AM and irbesartan monotherapy as part of the initial strategy for antihypertensive therapy. The role of each component of Concor AM in modern therapy for patients with cardiovascular diseases is considered.

Keywords: amlodipine, bisoprolol, combination therapy, arterial hypertension

References

1. European Society of Hypertension – European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21 (6): 1011–53. DOI: 10.1097/00004872-200306000-00001
2. Dahlöf B, Sever PS, Poulter NR et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895–906. DOI: 10.1016/S0140-6736(05)67185-1
3. Dahlöf B, Devereux RB, Kjeldsen SE et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359 (9311): 995–1003. DOI: 10.1016/S0140-6736(02)08089-3
4. Williams B, Mancia G, Spiering W et al; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33): 3021–04. DOI: 10.1093/eurheartj/ehy339
5. Mancia G, De Backer G, Dominiczak A et al; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25 (9): 1751–62. DOI: 10.1097/HJH.0b013e3282f0580f
6. Mancia G, Kjeldsen SE, Kreutz R et al. Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. Hypertension 2022; 79 (6): 1153–66. DOI: 10.1161/HYPERTENSIONAHA.122.19020
7. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71 (6): e13-e115. DOI: 10.1161/HYP.0000000000000065
8. Williams B, MacDonald TM, Morant S et al; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386 (10008): 2059–68. DOI: 10.1016/S0140-6736(15)002
9. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353 (9146): 9–13. DOI: 10.1016/S0140-6736(98)11181-9
10. Düngen HD, Apostolovic S, Inkrot S et al; CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail 2011; 13 (6): 670–80. DOI: 10.1093/eurjhf/hfr020
11. Jamerson K, Weber MA, Bakris GL et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359 (23): 2417–28. DOI: 10.1056/NEJMoa0806182
12. Rothwell PM, Howard SC, Dolan E et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375 (9718): 895–905. DOI: 10.1016/S0140-6736(10)60308-X
13. Clark D 3rd, Nicholls SJ, St John J et al. Visit-to-Visit Blood Pressure Variability, Coronary Atheroma Progression, and Clinical Outcomes. JAMA Cardiol 2019; 4 (5): 437–43. DOI: 10.1001/jamacardio.2019.0751
14. Yoo JE, Shin DW, Han K et al. Blood Pressure Variability and the Risk of Dementia: A Nationwide Cohort Study. Hypertension 2020; 75 (4): 982–90. DOI: 10.1161/HYPERTENSIONAHA.119.14033
15. Liu M., Chen X, Zhang S et al. Assessment of Visit-to-Visit Blood Pressure Variability in Adults With Optimal Blood Pressure: A New Player in the Evaluation of Residual Cardiovascular Risk? J Am Heart Assoc 2022; 11 (9): e022716. DOI: 10.1161/JAHA.121.022716
16. de Havenon A, Petersen N, Wolcott Z et al. Effect of dihydropyridine calcium channel blockers on blood pressure variability in the SPRINT trial: a treatment effects approach. J Hypertens 2022; 40 (3): 462–9. DOI: 10.1097/HJH.0000000000003033
17. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390 (10100): 1345–422. DOI: 10.1016/S0140-6736(17)32366-8
18. Komajda M, Follath F, Swedberg K et al; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24 (5): 464–74. DOI: 10.1016/s0195-668x(02)00700-5
19. Heidenreich PA, Bozkurt B, Aguilar D et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145 (18): e876–e894. DOI: 10.1161/CIR.0000000000001062
20. Lee SE, Lee HY, Cho HJ et al. Reverse J-Curve Relationship Between On-Treatment Blood Pressure and Mortality in Patients With Heart Failure. JACC Heart Fail 2017; 5 (11): 810–19. DOI: 10.1016/j. jchf.2017.08.015
21. Abraham WT, Fonarow GC Albert NM et al; OPTIMIZE-HF Investigators and Coordinators. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 2008; 52 (5): 347–356. DOI: 10.1016/j.jacc.2008.04.028
22. Pinho-Gomes AC, Rahimi K. Management of blood pressure in heart failure. Heart 2019; 105 (8): 589–95. DOI: 10.1136/heartjnl-2018-314438
23. Rethy L, Vu TT, Shah N.S et al. Blood Pressure and Glycemic Control Among Ambulatory US Adults With Heart Failure: National Health and Nutrition Examination Survey 2001 to 2018. Circ Heart Fail 2022; 15 (5): e009229. DOI: 10.1161/CIRCHEARTFAILURE. 121.009229
24. Packer M, Carson P, Elkayam U et al; PRAISE-2 Study Group. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). JACC Heart Fail 2013; 1 (4): 308–14. DOI: 10.1016/j.jchf.2013.04.004
25. Gottwald-Hostalek U, Sun N, Barho C, Hildemann S. Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine. Clin Pharmacol Drug Dev 2017; 6 (1): 9–18. DOI: 10.1002/cpdd.309
26. Hostalek-Gottwald U, Gaciong Z. A growing evidence base for the fixed-dose combination of bisoprolol and amlodipine to manage hypertension. Curr Med Res Opin 2022; 38 (7): 1047–53. DOI: 10.1080/03007995.2022.2072087
27. Hostalek U, Koch EMW. Treatment of hypertension with a fixed-dose combination of bisoprolol and amlodipine in daily practice: results of a multinational non-investigational study. Cardiovasc Disord Med 2016; 1 (3): 1–5. DOI: 10.15761/CDM.1000118
28. Чесникова А.И., Сафроненко В.А., Коломацкая О.Е. Оценка эффективности фиксированной комбинации бисопролола и амлодипина в амбулаторном лечении больных артериальной гипертензией и ишемической болезнью сердца. Кардиология. 2014; 54 (9): 17–23. DOI: 10.18565/cardio.2014.9.17-23
[Chesnikova A.I., Safronenko V.A., Kolomatskaia O.E. Otsenka effektivnosti fiksirovannoi kombinatsii bisoprolola i amlodipina v ambulatornom lechenii bol'nykh arterial'noi gipertenziei i ishemicheskoi bolezn'iu serdtsa. Kardiologiia. 2014; 54 (9): 17–23. DOI: 10.18565/cardio.2014.9.17-23 (in Russian).]
29. Rana R, Patil A. Efficacy and safety of bisoprolol plus amlodipine fixed dose combination in essential hypertension. Indian Pract 2008; 61 (4): 225–34.
30. Mehta S, Shah M, Shah A. Efficacy and tolerability of a fixed dose combination of amlodipine and bisoprolol in essential hypertension. Indian Pract 2005; 58 (12): 751–9.
31. Gottwald-Hostalek U, Li L, Montenegro P. Bisoprolol/amlodipine combination therapy improves blood pressure control in patients with essential hypertension following monotherapy failure. Curr Med Res Opin 2016; 32 (10): 1735–43. DOI: 10.1080/03007995.2016.1205573
32. Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension. URL: https://ichgcp.net/clinical-trials-registry/NCT01977794.
33. Knuuti J Wijns W, Saraste A, Capodanno D et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41 (3): 407–77. DOI: 10.1093/eurheartj/ehz425
34. Manolis AJ, Ambrosio G, Collins P et al. Impact of stable angina on health status and quality of life perception of currently treated patients. The BRIDGE 2 survey. Eur J Intern Med 2019; 70: 60–7.
DOI: 10.1016/j.ejim.2019.09.013
35. Chow CK, Atkins ER, Hillis G.S et al; QUARTET Investigators. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet 2021; 398 (10305): 1043–52. DOI: 10.1016/S0140-6736(21)01922-X

For citation:Gilyarevsky S.R., Golshmid M.V., Bendeliani N.G., Kuzmina I.M. History of combined protection: 25 years of using the fixed-dose combination of amlodipine and bisoprolol in clinical practice. Clinical review for general practice. 2022; 3: 22–28. DOI: 10.47407/kr2022.3.3.00131

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice